CAMBRIDGE, Mass. – October 17, 2022–Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) today presented additional data from the Phase 3 SKYLARK Study of zuranolone in adult women with postpartum depression (PPD), at the 35th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 15-18, 2022, in Vienna, Austria. This was the first time the SKYLARK Study was presented at a medical congress. Zuranolone is an investigational therapy being evaluated as a

SAN DIEGO, Oct. 13, 2022 /PRNewswire/ -- Neurelis, Inc., today announced findings from a novel, investigational analysis of the time between seizure clusters in pediatric patients using VALTOCO® (diazepam nasal spray). Findings indicate a significant increase in these intervals, or SEIzure interVAL (SEIVAL) data, over a 12-month period. This data will be presented at the 51st Child Neurology Society Annual Meeting in Cincinnati, Ohio, Oct. 12-15, 2022. VALTOCO, a nasal spray for acute treatment

LEXINGTON, Mass.--(BUSINESS WIRE)-- Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that the company will be presenting a poster on the mechanism of action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium at the poster session "Molecular Targeted Agents 1" on Wednesday, October 26, 2022 (Abstract No. 71). Cyteir shared preliminary evidence that CYT-0851 targ

SECAUCUS, N.J., Oct. 11, 2022 /PRNewswire/ -- More than two years after the COVID-19 pandemic began, diagnoses of breast and prostate cancer, two of the nation's leading causes of cancer death, continue to lag behind pre-pandemic levels, according to a nationally representative Quest Diagnostics Health Trends® study by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services. Published today in the Journal of Clinical Oncology (JCO) Clinical Cancer Informati

Led by a former tobacco company executive, Qnovia looks to offer nicotine replacement therapy through inhaled drug delivery. Brian Quigley spent just over 16 years at tobacco giant Altria. During his time there, he ran two U.S. business units, including the smokeless tobacco business. In July 2020, he joined founder and then-CEO at Qnovia (then Respira Technologies) Mario Danek as chief operating officer. Now CEO, with Danek as chief technology officer, Quigley leads the company as it looks to

BANJUL, Oct 7 (Reuters) - Gambia's President Adama Barrow on Friday said a surge in acute kidney injuries likely linked to a paracetamol syrup that killed dozens of children in past months was under control, with only two diagnoses in the last two weeks. Authorities launched a probe last month after doctors in July noticed that a number of children developed symptoms after taking a locally-sold paracetamol syrup used to treat fevers. Kidney injuries caused 66 child deaths in the past three month

The average star rating for Medicare Advantage plans with drug coverage in 2023 will be 4.15 stars out of five, a drop from the record high of 4.37 stars in 2022, the Centers for Medicare & Medicaid reported Thursday. The average for 2023 is similar to 2020 and 2021, when it was at 4.16 stars and 4.06 stars, respectively. There are 260 MA plans with Part D coverage that received four stars or more for 2023, a share of about 51%. This is a steep drop from 2022, when there were 322 plans with fou

Hemlibra Accounted For More Than 85% Of Global Bispecific Antibodies Sales In 2021 Global Bispecific Antibody Market Insight 2028 Report Highlights: Detailed Market Sales & Trends Insight Quarterly & Yearly Sales Insight Of Approved Antibodies Till Q1 2022 Global and Regional Market Analysis Global Bispecific Antibody Market Opportunity Assessment: > USD 20 Billion Market Sales Insight 2020 Till 2028 Approved Drug Sales Forecast Till 2028 Approved Drug In Market: 4 Drugs Ongoing Clin